<--- Back to Details
First PageDocument Content
RTT / Infectious causes of cancer / Chlamydia infections / Sexually transmitted diseases and infections / Infections with a predominantly sexual mode of transmission / Sexually transmitted infection / Non-gonococcal urethritis / Vaginitis / Dyspareunia / Urinary tract infection / Candidiasis / Trichomoniasis
Date: 2016-06-21 10:10:41
RTT
Infectious causes of cancer
Chlamydia infections
Sexually transmitted diseases and infections
Infections with a predominantly sexual mode of transmission
Sexually transmitted infection
Non-gonococcal urethritis
Vaginitis
Dyspareunia
Urinary tract infection
Candidiasis
Trichomoniasis

Microsoft Word - STI eng.doc

Add to Reading List

Source URL: lysistrada.ch

Download Document from Source Website

File Size: 155,47 KB

Share Document on Facebook

Similar Documents

Medicine / Clinical medicine / Pain / Health / Dyspareunia / Bloating

Doctor’s name Address Phone; fax numbers

DocID: 1q1lo - View Document

Microsoft Word - STI eng.doc

Microsoft Word - STI eng.doc

DocID: 1pvl2 - View Document

The	
  ENPOWR	
  Project	
  	
  	
  	
  FACT	
  SHEET	
   	
     	
   	
  

The  ENPOWR  Project        FACT  SHEET          

DocID: 1aY2Q - View Document

Vulvodynia: An Under-Recognized Pain Disorder Affecting 1 in 4 Women and Adolescent Girls Integrating Current Knowledge into Clinical Practice Reference List Section 1: Historical Perspective Haefner HK. Report of the In

Vulvodynia: An Under-Recognized Pain Disorder Affecting 1 in 4 Women and Adolescent Girls Integrating Current Knowledge into Clinical Practice Reference List Section 1: Historical Perspective Haefner HK. Report of the In

DocID: 1anWy - View Document

Shionogi receives Marketing Authorisation approval for Senshio® (ospemifene) in Europe for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women Osaka, Japan January 1

Shionogi receives Marketing Authorisation approval for Senshio® (ospemifene) in Europe for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women Osaka, Japan January 1

DocID: 1a1DJ - View Document